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Type 2 diabetes mellitus (T2DM) has consistently been associated with decreased risk of prostate cancer; however, if this decrease is
related to the use of anti-diabetic drugs is unknown. We prospectively studied men in the comparison cohort in the Prostate Cancer
data Base Sweden 3.0, with data on T2DM, use of metformin, sulfonylurea and insulin retrieved from national health care registers
and demographic databases. Cox proportional hazards regression models were used to compute hazard ratios (HR) and 95% confi-
dence intervals (CI) of prostate cancer, adjusted for confounders. The study consisted of 612,846 men, mean age 72 years (standard
deviation; SD59 years), out of whom 25,882 men were diagnosed with prostate cancer during follow up, mean time of 5 years
(SD53 years). Men with more than 1 year’s duration of T2DM had a decreased risk of prostate cancer compared to men without
T2DM (HR50.85, 95% CI50.82–0.88) but among men with T2DM, those on metformin had no decrease (HR50.96, 95% CI50.77–
1.19), whereas men on insulin (89%) or sulfonylurea (11%) had a decreased risk (HR50.73, 95% CI50.55–0.98), compared to men
with T2DM not on anti-diabetic drugs. Men with less than 1 year’s duration of T2DM had no decrease in prostate cancer risk
(HR51.11, 95% CI50.95–1.31). Our results gave no support to the hypothesis that metformin protects against prostate cancer as
recently proposed. However, our data gave some support to an inverse association between T2DM severity and prostate cancer risk.
Type 2 diabetes mellitus (T2DM) has consistently been asso-
ciated with decreased risk of prostate cancer1–6 and recent
data have suggested that the decrease in risk is related to the
use of anti-diabetic drugs.7 In particular metformin, currently
one of the most commonly prescribed anti-diabetic drugs,
has been recently investigated with inconsistent results; some
studies have found a decreased risk of prostate cancer among
metformin users,8–10 while others have found no
association.11–14 However, several of these studies have not
included data on diabetes mellitus type, duration, or severity,
which is essential to distinguish the effect of the T2DM diag-
nosis per se from use of anti-diabetic drugs. Furthermore,
detailed data on the date of onset of T2DM, anti-diabetic
drug use and prostate cancer are necessary to investigate
potential detection bias,15,16 and other time-related biases17,18
that could inﬂuence the association.
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Abbreviations: ATC: anatomical therapeutic chemical; BPH: benign prostatic hyperplasia; CCI: Charlson comorbidity index; CI: confidence
interval; HR: hazard ratio; PCBaSe: prostate cancer data base Sweden; PSA: prostate-specific antigen; SD: standard deviation; T1DM:
Type 1 diabetes mellitus; T2DM: Type 2 diabetes mellitus
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The aim of study was to assess the risk of prostate cancer
for men with T2DM in a large population-based cohort study,
taking duration of T2DM, use and duration of anti-diabetic
drugs, prostate cancer risk categories, comorbidity and socio-
economic status into account. To investigate the role of T2DM
and possible detection bias related to diagnostic activity related
to lower urinary tract symptoms, we also assessed the risk of
benign prostatic hyperplasia for men with T2DM.
Material and Methods
Comparison cohort in the prostate cancer data base
Sweden 3.0
Our study was designed as a prospective study in the com-
parison cohort in the Prostate Cancer data Base Sweden
(PCBaSe) 3.0, which consists of men free from prostate can-
cer selected from the Swedish population.19 For each man
with prostate cancer in the National Prostate Cancer Register
(NPCR) of Sweden, ﬁve prostate cancer-free men were select-
ed into the comparison cohort, matched on birth year and
county of residence. Using the Swedish 10-digit personal
identity number men with prostate cancer and prostate
cancer-free men were linked to other national health care
registers and demographic databases.
We retrieved data from the National Patient Register on
discharge diagnoses from hospital admissions up to 10 years
prior to the date of inclusion in the comparison cohort and
these data were used to calculate Charlson Comorbidity Index
(CCI) as previously described.20,21 CCI was categorized into
four groups: CCI 05 no comorbidity, and CCI 1, 2 and 3.
Data on educational level were retrieved from the Longitudinal
Integration Database for Health Insurance and Labor Market
Studies at Statistics Sweden and categorized into three groups:
9 years, 10–12 years, and 13 years.22 Date and cause of
death were obtained from the Cause of Death Register.
Start of study period was January 1, 2006, and end of study
period was date of prostate cancer diagnosis, death, or December
31, 2013, whichever came ﬁrst. To get a broader understanding of
the association between T2DM and prostatic diseases, we also
investigated the risk of a diagnosis of benign prostatic hyperplasia
(BPH, International Classiﬁcation of Diseases, 10th revision, code
N409) obtained from the National Patient Register as a proxy for
diagnostic activity related to lower urinary tract symptoms.
Identification of men with T2DM
The National Diabetes Register of Sweden, initiated in 1996,
has steadily increased its coverage and included 92% of the
estimated number of prevalent cases of diabetes mellitus in
2013.23 Men registered in the National Diabetes Register have
recorded details of diabetes mellitus including year of onset
and type and were thus considered to have complete data on
diabetes mellitus for the purpose of our study.24 Men with a
registered diagnosis of T2DM (International Classiﬁcation of
Diseases, 10th revision, code E11.0–11.9) in the National
Patient Register or in the Cause of Death Register, or men with
at least two ﬁlled prescriptions of an anti-diabetic drug in the
Prescribed Drug Register were considered to have a diagnosis
of diabetes mellitus, but with unknown onset year and type.
We imputed data on onset year and type of diabetes for these
men by use of multiple imputation based on predicted mean
matching with ﬁve imputed datasets.25 Educational level, CCI,
date of ﬁlled anti-diabetic drug prescriptions and ﬁrst regis-
tered date of T2DM diagnosis, or date of death due to T2DM,
were used as independent variables for the imputation. After
the imputation all men with diabetes mellitus were considered
as complete cases with data on onset year and type. For men
with T2DM, date of onset was set as July 1 of the registered or
imputed onset year, ﬁrst date of ﬁlled anti-diabetic drug pre-
scription or date of T2DM as registered in the National Patient
Register, whichever event came ﬁrst.
Subgroup study of men with T2DM
To study risk of prostate cancer for men treated with anti-
diabetic drugs, we analyzed a subgroup of men with a T2DM
onset after the start of the study period. This group of men had
detailed information on anti-diabetic drug prescriptions from
the Prescribed Drug Register speciﬁcally on metformin (Ana-
tomical Therapeutic Chemical; ATC code A10BA or A10BD),
insulin (ATC code A10A) and sulfonylurea (ATC code A10BB).
We categorized men with T2DM into three ordered groups: no
anti-diabetic drugs, metformin and insulin/sulfonylurea. These
groups were based on the assumption that men who had ﬁlled a
prescription for one or several anti-diabetic drugs had continued
to ﬁll prescriptions for these drugs. Men in the metformin group
had ﬁlled prescriptions metformin only, while men in the insu-
lin/sulfonylurea group could also have ﬁlled prescriptions for
metformin. The start date was deﬁned as the date of the ﬁrst
ﬁlled prescription of each anti-diabetic drug.
Endpoints
Data on prostate cancer diagnosis were obtained from NPCR
that includes information on date of diagnosis, age at diagno-
sis, tumor stage, Gleason score, serum levels of prostate-
speciﬁc antigen (PSA) at time of diagnosis and primary
What’s new?
Although Type 2 diabetes mellitus (T2DM) increases the risk of several cancers, multiple studies point toward a significantly
inverse relationship between T2DM and prostate cancer risk in men. Use of the anti-diabetic drug metformin is suspected of
underlying the association. In this prospective study in Sweden, however, metformin failed to decrease the risk of prostate
cancer. By comparison, risk was decreased in association with the use of insulin or sulfonylurea. These findings add some
support to an inverse association between T2DM severity and prostate cancer risk.
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treatment.19 Prostate cancer risk categories were deﬁned accord-
ing to a modiﬁcation of the National Comprehensive Cancer
Network Guideline as previously described26: Low-risk: T1-2,
Gleason score 2–6 and PSA< 10 ng/ml; intermediate-risk: T1-2,
Gleason score 7 and/or PSA 10–20 ng/ml; high-risk: T3 and/or
Gleason score 8–10 and/or PSA 20–50 ng/ml; metastatic disease:
T4 and/or N1 and/or PSA 50–100 ng/ml (regional metastases) or
M1 and/or PSA> 100 ng/ml (distant metastases).19
Statistical analysis
Risk of prostate cancer was calculated by use of hazard ratios
(HR) in time-updated Cox proportional hazard regression mod-
els with age as time-scale, adjusted for educational level and CCI
and stratiﬁed within the model for county of residence. Onset
date of T2DM was used as a time-updated covariate when evalu-
ating the effect of T2DM on prostate cancer risk, whereas in the
subgroup analysis of men with T2DM date of ﬁrst prescription
of metformin or insulin/sulfonylurea was used as a time-
updated covariate. The assumption of proportional hazards was
tested with Schoenfeld residuals and found valid.
In the full study cohort, risk of prostate cancer was calcu-
lated for men with T2DM versus men without T2DM. To
investigate a possible detection bias close to date of T2DM
onset, we calculated risk of prostate cancer during the ﬁrst
year after T2DM onset, and more than 1 year after T2DM
onset. Risk of prostate cancer in different risk categories was
calculated similarly. We investigated the association between
T2DM and BPH in a Cox model with the same adjustments
and stratiﬁcations as described above.
In the subgroup of men with T2DM, risk of prostate can-
cer was calculated for men treated with metformin or insu-
lin/sulfonylurea compared to men not treated with anti-
diabetic drugs. To distinguish between the association
between duration of T2DM and anti-diabetic drug use to
prostate cancer risk, we calculated risk of prostate cancer
during the ﬁrst year and for more than 1 year after T2DM
onset, and for less than or more than 1 year duration of anti-
Figure 1. Selection of study population from the comparison cohort
in the Prostate Cancer data Base Sweden 3.0a Mean of five impu-
tationsb Men with registered date of anti-diabetic drug prescription
(n52) or date of prostate cancer diagnosis (n51) after date of
death were excluded.
Table 1. Baseline characteristics of study population in Prostate Can-
cer data Base Sweden (PCBaSe), based on mean values of five
imputations
Study cohort1
Subgroup of men
with T2DM
N (%) N (%)
Study population 612,846 25,238
Age at start of study
59 years 60,552 (10) 1,273 (5)
60–64 years 91,557 (15) 3,221 (13)
65–69 years 115,846 (19) 5,385 (21)
70–74 years 109,449 (18) 5,592 (22)
75–79 years 99,901 (16) 4,935 (20)
80 years 135,541 (22) 4,836 (19)
Educational level2
9 years 275,724 (45) 11,826 (47)
10–12 years 218,070 (36) 9,215 (37)
13 years 119,052 (19) 4,201 (17)
Charlson comorbity index
No comorbidity 456,085 (74) 19,888 (79)
1 82,521 (13) 3,373 (13)
2 44,358 (7) 1,405 (6)
3 29,882 (5) 576 (2)
Mean years in follow up (SD) 5(3) 4(2)
1The maximum difference between the imputed dataset was 38 men.
2Educational level missing for 10,691 men (2%); these men were
included in the group with 9 years.
Abbreviations: Standard deviation (SD).
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diabetic drugs. Risk of prostate cancer classiﬁed into risk cat-
egories was analyzed similarly, but due to the limited size of
the study population these risk categories were merged into
two groups: favorable cancer that consisted of low-risk and
intermediate-risk, and aggressive cancer that consisted of
high-risk and metastatic disease.
All analyses were performed with STATA MP/2 version
14.0 (StataCorp LP, College Station, TX). The study was
approved by The Research Ethics Board at Umeå University,
Sweden.
Results
In the full study cohort of 612,846 men, a total of 119,571
men were diagnosed with T2DM during a mean follow-up
time of 5 years (SD5 3 years), 25,882 men were diagnosed
with prostate cancer (Fig. 1 and Table 1). A timeline with
dates used in the study is shown in Figure 2. Men with
T2DM were identiﬁed in one or several of the registers as
shown in Figure 3. Men with a duration of T2DM of more
than 1 year had a decreased risk of prostate cancer compared
to men without T2DM (HR5 0.85, 95% CI5 0.82–0.88)
Figure 2. Timeline of recruitment of study population from the comparison cohort in the Prostate Cancer data Base Sweden 3.0. [Color fig-
ure can be viewed at wileyonlinelibrary.com]
Figure 3. Proportion of men identified with Type 2 diabetes melli-
tus (T2DM) diagnosis in National Registers.
Table 2. Hazard ratios (HR) and 95% confidence intervals of prostate
cancer for men with Type 2 diabetes mellitus (T2DM)
Person-years # Cases HR (95% CI)
No T2DM 2,552,690 21,931 1.00 (ref)
T2DM 525,210 3,951 0.86 (0.83–0.90)
T2DM duration
<1 year
26,971 259 1.11 (0.95–1.31)
T2DM duration
>1 year
498,240 3,691 0.85 (0.82–0.88)
Cox regression models were based on time-updated data of T2DM
onset and adjusted for educational level, CCI and stratified for county.
The hazard ratios are mean values based on regression models from
five imputations.
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(Table 2). The risk was decreased for low-risk, intermediate-
risk and metastatic prostate cancer (Supporting Information
Table S1). Men with a duration of T2DM of less than 1 year
had no decreased risk (HR5 1.11, 95% CI5 0.95–1.31). Risk
of BPH was increased in men with a duration of T2DM of
less than 1 year (HR5 1.39, 95% CI5 1.28–1.52), whereas
men with more than 1 year duration had a smaller increase
in risk of BPH (HR5 1.04, 95% CI5 1.01–1.06).
In the subgroup of 25,238 men with T2DM and detailed
information on anti-diabetic drug use, 759 men were diag-
nosed with prostate cancer during a mean follow-up time of
4 years (SD5 2 years). Compared to men not treated with
anti-diabetic drugs, men on metformin had no increased risk
of prostate cancer (HR5 0.96, 95% CI5 0.77–1.19), whereas
men on insulin (89%) or sulfonylurea (11%) had a decreased
risk (HR5 0.73, 95% CI5 0.55–0.98) (Table 3). Men with a
duration of T2DM of less than 1 year who were on metfor-
min had an increased risk (HR5 1.49, 95% CI5 1.11–1.99),
and in an analysis of prostate cancer risk categories, these
men had a particularly increased risk of favorable cancer
(HR5 1.76, 95% CI5 1.17–2.66) (Supporting Information
Table S2A), whereas risk of aggressive cancer was not associ-
ated with any of the combinations of anti-diabetic drugs or
duration of T2DM (Supporting Information Table S2B).
Discussion
In this large population-based cohort study with comprehen-
sive data on T2DM, anti-diabetic drug use, prostate cancer
risk categories and putative confounders, we found no
decrease in risk of prostate cancer for men on metformin
compared to men with T2DM not treated with anti-diabetic
drugs. In contrast, we found a decreased risk of prostate can-
cer for men on insulin or sulfonylurea.
Strengths of our study include access to several high-
quality, nationwide, population-based registers with detailed
data on T2DM, anti-diabetic drug prescriptions, prostate can-
cer characteristics and confounding factors including comor-
bidity and socioeconomic factors.19,23 We investigated several
aspects of time-related associations: age, time-updated analy-
sis of date of T2DM onset and anti-diabetic drug use and
duration of T2DM. Furthermore, duration of T2DM was
analyzed to investigate detection bias or reverse causa-
tion.15,16 To further assess if there was detection bias we used
data on BPH as a proxy for diagnostic activity for lower uri-
nary tract symptoms that can be present at the onset of dia-
betes. To distinguish between the association between T2DM
and prostate cancer risk and anti-diabetic drugs and prostate
cancer risk, we investigated a subgroup of men with onset
date of T2DM after the start date of the Prescribed Drug
Register. Limitations of our study included a relatively short
follow-up time and a high mean age of the study population;
however, there was a wide range in age from 50 to 101 years
and we found no evidence that the association between
T2DM and prostate cancer differed according to age. Other
limitations of the study were the lack of data of risk factors
of prostate cancer, for example, family history and body
mass index, and this may have resulted in residual
confounding.
Our overall risk estimates for prostate cancer for men
with T2DM are in accordance with previous reports.1,4,5,27–30
In line with previous studies, shorter duration of T2DM was
not associated with decreased risk of prostate cancer, whereas
longer duration of T2DM was associated with a decreased
risk.1,8,15–17,29,31,32 For men with long T2DM duration, we
found a decreased risk of both favorable and aggressive can-
cer, essentially in accordance with previous studies that have
reported a decreased risk of localized prostate cancer28,30,32,33
and all prostate cancer.1,34,35 Furthermore, men with T2DM
in our study had an increased risk of BPH in accordance
with previous studies,36,37 and this risk was higher during the
ﬁrst year after T2DM onset, speculatively caused by detection
bias due to investigation of urinary tract symptoms. To the
best of our knowledge, no previous study has investigated
risk of BPH taking duration of T2DM into account. We
speculate that increase in diagnostic work-up of lower uri-
nary tract symptoms including PSA testing and subsequent
biopsies, sometimes initiated due to glucosuria in men with
newly diagnosed T2DM, will increase the probability of pros-
tate cancer detection.38,39
In the subgroup of men with T2DM with more than 1
year disease duration, we found no decrease in risk of pros-
tate cancer for men on metformin and a weak decrease in
Table 3. Hazard ratios (HR) and 95% confidence intervals of prostate cancer according to anti-diabetic drug usage in the subgroup of men
with Type 2 diabetes mellitus (T2DM)
T2DM duration<1 year T2DM duration>1 year
Person-years # Cases HR (95% CI) Person-years # Cases HR (95% CI)
No anti-diabetic drugs 15,410 148 1.21 (0.93–1.58) 29,802 257 1.00 (ref)
Metformin<1 year 6,136 67 1.49 (1.11–1.99) 4,138 27 0.84 (0.55–1.27)
Insulin/sulfonylurea<1 year 2,215 27 1.51 (0.99–2.30) 2,529 11 0.54 (0.29–0.99)
Metformin>1 year NA NA NA 20,558 157 0.96 (0.77–1.19)
Insulin/sulfonylurea >1 year NA NA NA 10,320 65 0.73 (0.55–0.98)
Cox regression models were based on time-updated data of anti-diabetic drugs and adjusted for educational level, CCI and stratified for county. The
hazard ratios are mean values based on regression models from five imputations.
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risk for men on insulin/sulfonylurea compared to men with
T2DM not on anti-diabetic drugs. These results are in line
with previous studies on metformin in a similar setting.11,40
Other studies of men with T2DM have investigated the
association between metformin and risk of prostate cancer
with other referents than used in our study. One study inves-
tigated metformin versus sulfonylurea,14 one study compared
ever-users with never-users of metformin41 and three meta-
analyses looked at metformin versus all other therapies com-
bined.42–44 In brief, all these reports showed no difference
between groups for overall prostate cancer risk. In addition,
one study of insulin versus no insulin found a decreased risk
of prostate cancer in insulin users, but no difference in risk
when analyzing insulin versus other anti-diabetic drugs;13
another study of insulin versus other glucose-lowering agents
found no difference in risk.12 In contrast, other observational
studies found that men on metformin7,8,10 and insulin,1,7,8,31
versus men not treated with these anti-diabetic drugs, irre-
spective of T2DM status, had a decreased risk of prostate
cancer.
Putative mechanisms for the decreased risk of prostate
cancer for men with long duration of T2DM include low lev-
els of androgens,45 a genetic proﬁle with increased risk of
T2DM and decreased risk of prostate cancer,46 high all-cause
mortality and low PSA levels but large prostate thereby
decreasing the probability of biopsy and detection of small
indolent cancers.47,48 Our results can be generalized to popu-
lations with similar prostate cancer incidences and back-
ground mortality, that is, westernized countries.
In Sweden, metformin is the drug of choice for men with
incident T2DM in need of pharmacotherapy, and with dis-
ease progression other anti-diabetic drugs may be added at a
later stage. Thus, a majority of men with a newly diagnosed
T2DM will be prescribed metformin, as shown in our study.
In line with this, the National Diabetes Register reported that
men on insulin had a longer duration of T2DM and higher
levels of glycated hemoglobin compared to men on metfor-
min49 and men not on anti-diabetic drugs. High levels of gly-
cated hemoglobin and also insulin resistance have been
associated with decreased prostate cancer risk suggesting that
severe metabolic aberrations associated with poor T2DM
control are associated with a decreased risk of prostate
cancer.50
In conclusion, men with T2DM had a decreased risk of
prostate cancer and but there was no association between
metformin use and risk as previously proposed. More data
are needed to elucidate if there is an inverse association
between T2DM severity and prostate cancer risk.
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